Important:
Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.
UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.
Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.
This is the complete archive for the UpToDate Clinical Talk Podcasts.
Neonatal hypoglycemia; Hysteroscopic sterilization; Dabigatran reversal agent
Date Released: Jan 20 2016
This episode features Dr. Paul Rozance, discussing the management of neonatal hypoglycemia (starts at 01:13); Dr. Howard Sharp, discussing concerns related to hysteroscopic sterilization (starts at 11:55); and Dr. Lawrence Leung, discussing a new reversal agent for the direct oral anticoagulant dabigatran (starts at 21:46). Dr. Nancy Sokol hosts.
Dr. Paul Rozance is an Associate Professor of Neonatal Medicine at the University of Colorado in Denver, researcher at the Perinatal Research Center in Colorado, and a member of the Pediatric Endocrine Society Committee for Hypoglycemia in Neonates, Infants, and Children.
Dr. Howard Sharp is a Professor of Obstetrics and Gynecology, Division Chief of General Obstetrics and Gynecology, and Vice Chair of Clinical Affairs at the University of Utah.
Dr. Lawrence Leung is Professor of Medicine at Stanford University School of Medicine in the Division of Hematology and Chief of Staff at the VA Palo Alto Health Care System.Segment on neonatal hypoglycemia (Dr. Rozance):
- McKinlay CJ, Alsweiler JM, Ansell JM, et al. Neonatal Glycemia and Neurodevelopmental Outcomes at 2 Years. N Engl J Med 2015; 373:1507.
Segment on hysteroscopic sterilization (Dr. Sharp):
- Chudnoff SG, Nichols JE Jr, Levie M. Hysteroscopic Essure Inserts for Permanent Contraception: Extended Follow-Up Results of a Phase III Multicenter International Study. J Minim Invasive Gynecol 2015; 22:951.
Segment on dabigatran reversal agent (Dr. Leung):
- Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373:511.
Paul J Rozance, MD Nothing to disclose
Howard T Sharp, MD Nothing to disclose
Lawrence LK Leung, MD Nothing to disclose
Empagliflozin for diabetes; Pneumococcal vaccines; PCSK9 antibodies
Date Released: Dec 8 2015
This episode features Dr. David Nathan, discussing a diabetes drug, empagliflozin, and its impact on diabetes and cardiovascular outcomes (starts at 01:07); Dr. John Bartlett, discussing revisions to US recommendations for pneumococcal vaccination in older adults (starts at 09:30); and Dr. Mason Freeman, discussing use of the newly approved PCSK9 antibodies in the treatment of hyperlipidemia (starts at 17:53). Dr. Nancy Sokol hosts.
Dr. David Nathan is a Professor of Medicine at Harvard Medical School and Director of the Diabetes Center at Massachusetts General Hospital in Boston.
Dr. John Bartlett is a Professor Emeritus at the Johns Hopkins University School of Medicine. He served as Chief of Infectious Diseases at Johns Hopkins School of Medicine from 1980-2007.
Dr. Mason Freeman is a Professor of Medicine at Harvard Medical School and Chief of the Lipid and Metabolism unit at Massachusetts General Hospital in Boston.Segment on empagliflozin (Dr. Nathan):
- Zinman, B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117.
Segment on pneumococcal vaccination (Dr. Bartlett):
- Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015; 64:944.
Segment on PCSK9 antibodies (Dr. Freeman):
- Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1488.
- Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500.
David M Nathan, MD Nothing to disclose
John G Bartlett, MD Nothing to disclose
Mason W Freeman, MD Grant/Research Support/Clinical Trial Support: Regeneron [LDL cholesterol treatment (Alirocumab)]; Sanofi [LDL cholesterol treatment (Alirocumab)].